Search Results
Your search for can matches 13758 pages
Showing 8551 - 8600ECCO 2017: Some Patients With Early-Stage Breast Cancer May Benefit More From Breast-Conserving Therapy Than Mastectomy
Breast-conserving therapy (breast-conserving surgery combined with radiation therapy) may be superior to mastectomy in certain patients with breast cancer, according to results from the largest study on this topic to date, presented at the 2017 European Cancer Congress (Abstract 4LBA). Although...
ECCO 2017: Low Cause-Specific Mortality in Women Over 50 Treated for Ductal Carcinoma in Situ
Women over 50 who have been treated for ductal carcinoma in situ (DCIS) are more likely to be alive 10 years later than women in the general population, according to new research presented by Elshof et al at the 2017 European Cancer Congress (ECCO) (Abstract 173). DCIS differs from breast cancer...
Small-Intestine GIST Treated Surgically Associated With Better Prognosis in Younger Patients
Gastrointestinal stromal tumors (GIST) arise is the wall of the digestive tract and most often occur in the stomach or small intestine. Though more common in later in life, GISTs can occur in adolescents and young adults (AYA) under 40 years old as well. In an article published by Fero et al in...
Three Genetic Alterations Identified in Non–Down Syndrome Pediatric Acute Megakaryoblastic Leukemia
Research led by St. Jude Children’s Research Hospital has identified three genetic alterations to help identify high-risk pediatric patients with acute megakaryoblastic leukemia (AMKL) who may benefit from allogeneic stem cell transplants. The study, published by de Rooij et al in Nature...
ECCO 2017: Twice-Daily Radiation Therapy May Reduce Mortality in Head and Neck Cancer
Treating patients with head and neck cancer with hyperfractionated twice-daily radiation therapy combined with chemotherapy could potentially reduce mortality, according to new research presented by Petit et al at the 2017 European Cancer Congress (ECCO) (Abstract 823). The study, led by Claire...
SWOG Launches National Immunotherapy Clinical Trial for Rare Cancers
People with rare cancers now have the option of joining a national clinical trial testing leading-edge immunotherapies for a wide variety of tumor types. It’s the first federally funded immunotherapy trial devoted to rare cancers. Despite their name, rare cancers make up more than 20% of...
Philip E. Bourne, PhD, Leaves NIH, Accepts Position at University of Virginia
On January 6, Francis S. Collins, MD, PhD, Director, National Institutes of Health (NIH), issued the following statement: It is with truly mixed emotions that I announce the departure of Philip E. Bourne, PhD, who will be leaving his post as NIH’s first Associate Director for Data Science to...
Addition of Palifosfamide to Doxorubicin in Metastatic Soft-Tissue Sarcoma
In the phase III PICASSO III trial reported in the Journal of Clinical Oncology, Christopher W. Ryan, MD, of Oregon Health & Science University, and colleagues found that adding palifosfamide to doxorubicin did not prolong progression-free survival among patients with metastatic soft-tissue...
Kenneth C. Anderson, MD, Begins Term as 2017 ASH President
Kenneth C. Anderson, MD, an expert in multiple myeloma, will serve as President of the American Society of Hematology (ASH) for a year-long term through December 2017. Dr. Anderson is Director of the Lebow Institute for Myeloma Therapeutics and the Jerome Lipper Myeloma Center at Dana-Farber...
I’m Learning to Live With Chronic Cancer
I was feeling a bit more tired than usual as the Christmas holidays approached in December 2012, but I chocked it up to the frenetic pace of the season and keeping up with caring for my two young children, ages 4 and 12. I had none of the other typical warning signs of chronic myeloid leukemia...
Breast Cancer Researchers at Baylor Receive Komen Grants to Support Study of Drug Efficacy, Treatment Resistance
Two breast cancer researchers in the Baylor College of Medicine’s Lester and Sue Smith Breast Center, part of the Dan L. Duncan Comprehensive Cancer Center, have been awarded grants from the Susan G. Komen Foundation to support their research in drug efficacy in treating triple-negative breast...
What Have We Got to Lose?
Tuesday morning was the regular time for the departmental meeting—an opportunity to discuss cases, troubleshoot, debrief, and expedite the necessary allied health referrals. As usual, patient cases were being discussed in alphabetical order of the attending oncologist. We were already three...
Clinical Trials Actively Recruiting Patients With Bladder Cancer
Phase I Study Title: Ethacrynic Acid Elimination in Nonmuscle Invasive Bladder Cancer Patients Undergoing Transurethral Resection Study Type: Phase I/interventional/single-group assignment Study Sponsor and Collaborators: University of Kansas Medical Center Purpose: To provide quantitative...
What Cancer?
If they are honest, most oncologists who’ve practiced medicine for more than 15 years will tell you they’ve learned much more from their patients than their patients have learned from them. The life lessons I’ve learned from treating this complicated, resilient, and often cruel disease are many....
An Insider’s Account of the AIDS Epidemic
On June 5, 1981, the Centers for Disease Control and Prevention published a Morbidity and Mortality Weekly Report (MMWR) describing cases of a rare lung infection in five young gay men in Los Angeles. The men had other unusual infections as well, indicating their immune systems were compromised....
An Ovarian Cancer Survivor’s Story
Ovarian cancer, the deadliest of gynecologic cancers, is usually diagnosed after the disease has spread. Susan Evans was a secondary English and remedial reading teacher for 32 years in Bradford, Pennsylvania. She was on several advisory boards and was recognized by the Pennsylvania Senate and...
Vitamin D and Cancer: A Uniform Dose Is Unlikely to Fit All Patients
Technically, vitamin D is a secosteroid hormone, not a vitamin. Increasing evidence indicates that vitamin D exerts effects beyond calcium homeostasis. Importantly, for example, higher serum vitamin D levels are associated with better cancer outcomes, including survival.1-3 The protective effects...
Canadian Study Looks at an Integrated Palliative Care Model
Although initiation of palliative care from the time of cancer diagnosis produces optimal outcomes for patients, this strategy is often not practiced. A recent Canadian study conducted in patients with advanced cancer and their caregivers examined the opinions of patients with advanced cancer and...
ASCO Releases Principles for Patient-Centered Health-Care Reform
ASCO has released the “ASCO Principles for Patient-Centered Health-Care Reform,” seven recommendations designed to ensure access to high-quality cancer care amid the changing U.S. health-care delivery landscape. The principles aim to assist the new Congress and Administration, so, as they consider...
How ASCO’s New Health Policy Fellowship Program Is Helping Shape Future Cancer Care Policy
In October 2015, ASCO launched the Health Policy Fellowship program to help the next generation of oncologists with an interest in health policy to develop the skills and experience necessary to achieve their goals and shape cancer care policy in an increasingly complicated and diverse care...
Telemedicine: Transforming Health Care One Computer at a Time
Telehealth is the delivery of health care remotely via telecommunication tools. Its aim is to increase access to care, especially for patients with chronic diseases such as cancer and for populations for whom care is not always available. With the growing availability of broadband and portable...
Jennifer Lycette, MD, Takes Pride in Delivering Cancer Care to Those Most in Need in Northwest Oregon
Born and reared in Anchorage, a city located in Southcentral Alaska, farther north than St. Petersburg, Russia, Jennifer Lycette, MD, grew up during the 1970s and 1980s. “We were fairly isolated from the lower 48. We didn’t have cable TV in Anchorage, and I remember my father would turn off the TV ...
New President of the Skin Cancer Foundation Emphasizes Public Education to Reduce Skin Cancer Incidence and Deaths
The statistics on the rising rates of skin cancer are alarming. According to the Skin Cancer Foundation, each year over 5.4 million cases of nonmelanoma skin cancer are treated in more than 3.3 million people, and an additional 76,380 people are diagnosed with the deadliest form of skin cancer,...
Ibrutinib: A Potential Option for Chronic Graft-vs-Host Disease?
Currently, there is no U.S. Food and Drug Administration (FDA)-approved therapy for chronic graft-vs-host disease—a life-threatening consequence of stem cell or bone marrow transplant—that has not responded to corticosteroids, but this may be about to change. Ibrutinib (Imbruvica) achieved...
Survivorship Symposium 2017: Almost Half of Partners and Caregivers of Young Breast Cancer Survivors Experience Long-Lasting Anxiety
While evidence is mounting on the physical and emotional challenges many cancer caregivers experience, few studies have addressed the experience of partners of young adults with cancer. Now, a new study evaluating the psychosocial concerns and mental health in the partners of young survivors of...
AACR Receives $1.125 Million National Cancer Institute Grant to Continue Annual Clinical Trials Workshop
The American Association for Cancer Research (AACR) is pleased to announce that the National Cancer Institute (NCI) has awarded the organization a 5-year, $1.125 million grant to continue providing clinical fellow and junior faculty clinical researchers the opportunity to learn the essentials of...
Addressing Discrimination and Bias in Medical Education
“As a medical student, I often felt marginalized from my medical community. I have been told that my name is ‘not American,’ fallen prey to being confused for support staff such as a janitor (even while wearing my white coat) and been asked questions like, ‘Where are you really from?’ or ‘How old...
Vanderbilt Study to Explore Lymphedema Self-Care for Head and Neck Cancer Survivors
Vanderbilt University School of Nursing Assistant Professor Jie Deng, PhD, RN, has been awarded a $789,000 research scholar grant by the American Cancer Society to develop and test a self-care program for head and neck cancer survivors diagnosed with secondary lymphedema/fibrosis....
ASCO’s State Affiliate Council: Helping Practices to Meet the Challenges Ahead
ASCO’s State Affiliate Council serves as an advisory group to ASCO’s Board of Directors on issues relating to its State/Regional Affiliates and their members, and serves as a vehicle for effective communications between the Board and domestic membership. The Council is made up of physician...
ASCO Launches First Journal Dedicated to Precision Oncology
ASCO has launched a new journal dedicated to precision oncology, JCO Precision Oncology (JCO PO). JCO PO features original clinical research, scientific reviews, and editorials on genomics. James M. Ford, MD, the journal’s Editor-in-Chief, said JCO PO offers precision oncologists a place to...
Survivorship Symposium 2017: Physical and Psychological Factors Contribute to Decreased Physical Activity in 75% of Patients With Cancer
Although, in the past, patients with cancer were often counseled by their physicians to rest and reduce their physical activity, according to the American Cancer Society, emerging data are showing that exercise is not only safe and possible during cancer treatment, it can improve patients’...
World Cancer Day, The Campaign to Conquer Cancer, and Collaboration
Each year on February 4, people around the world come together to celebrate World Cancer Day. Founded in 2008 by the Union for International Cancer Control, World Cancer Day strives to raise awareness of and education about cancer as well as to encourage governments and individuals to take action....
Conquer Cancer Foundation Researcher Spotlight: Vamsidhar Velcheti, MD
What if more patients with lung cancer could benefit from immunotherapy? Although progress in this area of research is exciting, unfortunately, a vast majority of patients with thoracic malignancies do not respond to this pioneering form of treatment. Vamsidhar Velcheti, MD, Assistant Professor of ...
PARP Inhibitor Niraparib Yields ‘Unprecedented’ Results in Ovarian Cancer in Phase III Trial
The first phase III trial of an inhibitor of poly (ADP-ribose) polymerase (PARP) yielded unprecedented results in treating ovarian cancer. The trial was presented at the European Society for Medical Oncology (ESMO) in Copenhagen, Denmark, and electronically reported concurrently in The New England ...
Survivorship Symposium 2017: Younger Survivors of Thyroid Cancer Face Increased Risk of Hypertension, Heart Disease, and Osteoporosis
According to the American Cancer Society, in the United States, thyroid cancer is the most rapidly increasing cancer, tripling in the past 3 decades, and is commonly diagnosed at a younger age than most other adult cancers. A study by Blackburn et al examining whether survivors of thyroid cancer...
Understanding Cancer Epigenetics and Its Clinical Implications
The field of epigenetics emerged in the 1990s and has been described with somewhat variable meanings. In 2008, a meeting at the Cold Spring Harbor laboratory arrived at a definition of epigenetics by consensus: “A stably heritable phenotype resulting from changes in a chromosome without...
Diamonds Are Forever, Tyrosine Kinase Inhibitors Are Not?
Sir Donald Munger: “You have been on holiday, I understand. Relaxing, I hope?” James Bond: “Oh, hardly relaxing, but most satisfying.” (Diamonds Are Forever) As tyrosine kinase inhibitors became the mainstay of therapy for patients with chronic myeloid leukemia (CML), our assumption has been that...
Safety of Stopping Imatinib in CML With Undetectable Minimal Residual Disease for at Least 2 Years
As reported in the Journal of Clinical Oncology by Gabriel Etienne, MD, PhD, of the Institut Bergonié, Bordeaux, and colleagues, long-term follow-up in the French Stop Imatinib (STIM1) study indicates that imatinib can be safely stopped in patients with chronic myeloid leukemia (CML) with...
Falls in Older Patients With Cancer: Recognizing and Reducing the Risk
In older patients, a current or previous cancer diagnosis confers a 15% to 20% greater risk of suffering a fall.1 Defined as an “unexpected event in which the participant comes to rest on the ground, floor, or lower level,” a fall occurs in 30% to 50% of cancer patients 65 years of age or...
Nivolumab in Squamous Cell Carcinoma of the Head and Neck in CheckMate 141: Game Not Over
Most patients with squamous cell carcinoma of the head and neck present with locally advanced disease. With combined-modality approaches, the chance of cure ranges from < 50% to up to 80%, depending on the site, stage, and other risk factors, such as human papillomavirus (HPV) status. When...
New AACI President Stanton L. Gerson, MD, Aims to Integrate Cancer Treatment Advances Into the Community
Stanton L. Gerson, MD, became the new President of the Association of American Cancer Institutes (AACI) during the Association’s 2016 Annual Meeting in Chicago, held October 23–25. Dr. Gerson is the Asa and Patricia Shiverick–Jane Shiverick (Tripp) Professor of Hematological Oncology at the Case...
Chi Van Dang, MD, PhD, Appointed Scientific Director of the Ludwig Institute for Cancer Research
The Ludwig Institute for Cancer Research announced the appointment of Chi Van Dang, MD, PhD, as its Scientific Director. A hematologic oncologist and renowned researcher, Dr. Dang joins Ludwig from the University of Pennsylvania Perelman School of Medicine’s Abramson Cancer Center, which he has...
ASCO Endorses ASTRO Guideline on Radiation Therapy for Glioblastoma
As reported by Erik P. Sulman, MD, PhD, of MD Anderson Cancer Center, and colleagues in the Journal of Clinical Oncology, ASCO has endorsed the 2016 American Society for Radiation Oncology (ASTRO) evidence-based guideline on radiation therapy for glioblastoma.1 The endorsement was based on review ...
Optimizing Access to Fertility Preservation Options
Ensuring that people with cancer understand how cancer treatment could affect their fertility and what options are available for preserving fertility were widely recognized as top priorities by attendees of the 2016 Oncofertility Conference in Chicago. As detailed at the conference, means of...
Managing Breast Cancer in a Pregnant Patient
“One of the most challenging oncologic situations that I face as a clinician is the diagnosis of breast cancer in a young pregnant patient,” Jacqueline Jeruss, MD, PhD, Director of the Breast Care Center at the University of Michigan Comprehensive Cancer Center, Ann Arbor, told the more than 250...
Antiretroviral Agent Makes Strong Showing in Refractory Multiple Myeloma
An antiretroviral drug that is used for human immunodeficiency virus (HIV) demonstrated strong activity when combined with bortezomib (Velcade) in patients with relapsed/refractory multiple myeloma in a small multicenter phase II study presented at the 2016 American Society of Hematology (ASH)...
Brentuximab Vedotin Plus Nivolumab Highly Active in Relapsed Classical Hodgkin Lymphoma
Response rates of 90% to 100% were achieved in early studies evaluating the combination of brentuximab vedotin (Adcetris) and nivolumab (Opdivo) in relapsed or refractory classical Hodgkin lymphoma. The findings were presented at the 2016 American Society of Hematology (ASH) Annual Meeting &...
CAR T-Cell Therapy KTE-C19 Appears Successful in Aggressive B-Cell Lymphoma
Chimeric antigen receptor (CAR) T-cell therapy continues to have impressive showings in patients with aggressive hematologic malignancies and no other good treatment options. Interim results of the pivotal phase II ZUMA-1 trial, the first multicenter trial of the experimental CAR T-cell therapy...
Expert Point of View: Philip McCarthy, MD
The ASCO Post asked Philip McCarthy, MD, Professor of Oncology and Internal Medicine at Roswell Park Cancer, Buffalo, and Director of the Blood and Marrow Transplant Center there, to comment on these study findings. He first addressed the need to study earlier intervention for smoldering ...
High Response Rates to Triplet Therapy in Smoldering Myeloma
High-risk patients with smoldering multiple myeloma responded to a regimen of elotuzumab (Empliciti), lenalidomide (Revlimid), and dexamethasone, in a multicenter phase II study led by Irene Ghobrial, MD, of Dana-Farber Cancer Institute, Boston.1 “The high response rates among this patient...
